Experimental antibody aims to shield hearts after stent treatment
NCT ID NCT06678074
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a monoclonal antibody called atibuclimab (IC14) in 10 adults who had a severe heart attack (STEMI) and received a stent. The drug is given by IV to see if it can prevent further heart muscle damage and reduce inflammation. Participants are compared to those receiving a placebo to check safety and heart function improvements.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEMI are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Virginia
Charlottesville, Virginia, 22908-1394, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States